全文获取类型
收费全文 | 240篇 |
免费 | 18篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 32篇 |
口腔科学 | 1篇 |
临床医学 | 21篇 |
内科学 | 41篇 |
皮肤病学 | 2篇 |
神经病学 | 34篇 |
特种医学 | 10篇 |
外科学 | 53篇 |
综合类 | 1篇 |
预防医学 | 16篇 |
眼科学 | 12篇 |
药学 | 8篇 |
肿瘤学 | 25篇 |
出版年
2023年 | 3篇 |
2022年 | 10篇 |
2021年 | 9篇 |
2020年 | 7篇 |
2019年 | 14篇 |
2018年 | 6篇 |
2017年 | 8篇 |
2016年 | 9篇 |
2015年 | 9篇 |
2014年 | 8篇 |
2013年 | 9篇 |
2012年 | 17篇 |
2011年 | 20篇 |
2010年 | 12篇 |
2009年 | 9篇 |
2008年 | 16篇 |
2007年 | 17篇 |
2006年 | 27篇 |
2005年 | 13篇 |
2004年 | 10篇 |
2003年 | 10篇 |
2002年 | 7篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1995年 | 2篇 |
1991年 | 1篇 |
排序方式: 共有259条查询结果,搜索用时 57 毫秒
41.
42.
The compensation comparison (CC) method is a psychophysical technique to measure retinal stray light. It uses a two alternative forced choice (2AFC) measurement paradigm. The 25 binary (0 and 1) responses resulting from the 2AFC test are analyzed using maximum likelihood estimates. The likelihood function is used to give two quantities: the most likely stray-light level of the eye under investigation, and the accuracy of this estimate [called expected standard deviation (ESD)]. The CC method is used in 2422 subjects of the GLARE study. Each eye is tested twice to allow analysis of measurement repeatability. Furthermore, the large amount of responses is used to evaluate the shape of the psychometric function, for which a mathematical model is used. The shape of the psychometric function found by averaging the 0 and 1 responses fit well to the model function. Data sorted according to ESD show differences in the shape of the psychometric function between good and bad observers. These different shapes for the psychometric function are used to reanalyze the data, but the stray-light results remain virtually identical. ESD proves to be an efficient tool to detect unreliable measurements. In clinical practice, ESD may be used to decide whether to repeat a measurement. 相似文献
43.
44.
45.
E. Versteijne H. W. M. van Laarhoven J. E. van Hooft R. M. van Os E. D. Geijsen M. I. van Berge Henegouwen M. C. C. M. Hulshof 《Diseases of the esophagus》2015,28(5):453-459
A locoregional recurrence after definitive chemoradiation (dCRT) for patients with inoperable or unresectable esophageal cancer occurs in about 50% of the patients and is a major cause of failure with a poor prognosis. The aim of this study was to determine the pattern of locoregional recurrence and its prognostic factors after dCRT in order to search for improvements in radiation treatment. We retrospectively reviewed 184 patients treated with external beam radiotherapy (50.4 Gray/28 fractions), combined with weekly concurrent paclitaxel and carboplatin. Locoregional recurrences were defined by clinical signs of recurrent or progressive disease, combined with progression on computed tomography/positron emission tomography‐computed tomography scan, or suspicious endoscopic findings and/or histological proof of recurrence. The site of locoregional recurrence was analyzed with respect to the borders of the radiation fields. After a mean follow up of 22.8 months, 76 patients (41%) had evidence of locoregional recurrence. The 3‐years locoregional recurrence‐free rate was 45%. The majority of locoregional recurrences occurred within 12 months, nearly all within 24 months. The majority of these patients failed at the site of the primary tumor (86%). Infield locoregional recurrences at the site of the lymph nodes only occurred in 1% compared with 57% at the site of the primary tumor only. Outfield locoregional lymph node recurrences occurred in 22%, without infield recurrence occurred in only 4% of all patients. The 1‐, 3‐, and 5‐year overall survival was 65%, 28%, and 21%, respectively. The current analysis demonstrates that a locoregional recurrence after dCRT occurs in 41% of the patients, the majority at the site of the primary tumor. These data suggest a benefit of dose intensification of the primary tumor, but not at the site of the lymph nodes. Higher radiation doses should be assessed with prospective trials. 相似文献
46.
Stefan AW Bouwense Marjan de Vries Luuk TW Schreuder S?ren S Olesen Jens B Fr?kj?r Asbj?rn M Drewes Harry van Goor Oliver HG Wilder-Smith 《World journal of gastroenterology : WJG》2015,21(1):47-59
Pain in chronic pancreatitis(CP) shows similarities with other visceral pain syndromes(i.e.,inflammatory bowel disease and esophagitis),which should thus be managed in a similar fashion.Typical causes of CP pain include increased intrapancreatic pressure,pancreatic inflammation and pancreatic/extrapancreatic complications.Unfortunately,CP pain continues to be a major clinical challenge.It is recognized that ongoing pain may induce altered central pain processing,e.g.,central sensitization or pro-nociceptive pain modulation.When this is present conventional pain treatment targeting the nociceptive focus,e.g.,opioid analgesia or surgical/endoscopic intervention,often fails even if technically successful.If central nervous system pain processing is altered,specific treatment targeting these changes should be instituted(e.g.,gabapentinoids,ketamine or tricyclic antidepressants).Suitable tools are now available to make altered central processing visible,including quantitative sensory testing,electroencephalograpy and(functional) magnetic resonance imaging.These techniques are potentially clinically useful diagnostic tools to analyze central pain processing and thus define optimum management approaches for pain in CP and other visceral pain syndromes.The present review proposes a systematic mechanism-orientated approach to pain management in CP based on a holistic view of the mechanisms involved.Future research should address the circumstances under which central nervous system pain processing changes in CP,and how this is influenced by ongoing nociceptive input and therapies.Thus we hope to predict which patients are at risk for developing chronic pain or not responding to therapy,leading to improved treatment of chronic pain in CP and other visceral pain disorders. 相似文献
47.
Luuk Wieske Duncan Smyth Michael P. Lunn Filip Eftimov Charlotte E. Teunissen 《Neurotherapeutics》2021,18(4):2351
Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13311-021-01136-0. 相似文献
48.
49.
P. M. A. van Haaren M. C. C. M. Hulshof H. P. Kok S. Oldenborg E. D. Geijsen J. J. B. Van Lanschot 《International journal of hyperthermia》2013,29(8):663-674
Purpose. To analyse the relation between patients’ body size and temperatures during locoregional hyperthermia for oesophageal cancer.Methods. Patients were treated with neo-adjuvant chemoradiotherapy plus hyperthermia, given with the AMC-4 waveguide system. Temperatures were measured at tumour location in the oesophageal lumen using multisensor thermocouple probes. Systemic temperature rise (ΔTsyst) was monitored rectally. Steady-state tumour temperatures were expressed in terms of T90, T50 and T10, averaged over the five hyperthermia sessions, and correlated with patients’ body mass, dorsoventral and lateral diameter and fat layer thickness, measured at tumour level using a CT scan made in treatment position. Fat percentage (Fat%) was estimated using diameters and fat layer thickness. Effective tumour perfusion (Wb) was estimated from the temperature decay during the cool-down period.Results. Temperatures were inversely related to body mass, diameters, fat layer thickness, and fat percentage. The strongest univariate correlations were found with lateral fat layer thickness, lateral diameter, and body mass. An increase in lateral diameter (28→42 cm), or in lateral fat layer thickness (0→40 mm) or in body mass (50→120 kg) all yielded a ~1.5°C decrease in tumour temperature rise. Multivariate correlation analysis proved that the combination of Fat%, ΔTsyst and Wb was most predictive for the achieved tumour temperatures, accounting for 81 ± 12% of the variance in temperatures.Conclusions. Intra-oesophageal temperatures during locoregional hyperthermia are inversely related to patients’ body size parameters, of which fat percentage is the most significant prognostic factor. These findings could be used to define inclusion criteria of new studies on intrathoracic hyperthermia. 相似文献
50.